Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment.
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000006128
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Uncontrolled infections; - Active autoimmune diseases; - Serious cardiac disease; - Other cancers; - Received continuous systemic steroids; - Pregnant, to be pregnant, or nursing mothers; - Principle investigator or co-investigator judged to be inappropriate to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method